KPV Category 2 status: current compounding access explained
KPV cleared FDA Category 2 in April 2026 — but compounding pharmacies still can't legally prepare it yet.
TL;DR
- KPV's regulatory status changed on April 15, 2026 — the FDA removed it from Category 2.
- Removal isn't authorization — KPV still needs a Pharmacy Compounding Advisory Committee (PCAC) review before compounding.
- The PCAC discusses KPV on July 23, 2026. No decision has been made yet.
What is KPV Category 2 status?
KPV sat on the FDA's Section 503A (in plain English: the FDA rule covering custom-mixed pharmacy medicines) Category 2 list for years, which blocked pharmacies from preparing it. On April 15, 2026, the FDA removed KPV and 11 other peptides from Category 2 (FDA, 2026). KPV is a tripeptide (in plain English: a chain of three amino acids) made of lysine, proline, and valine. It is the C-terminal fragment of alpha-melanocyte-stimulating hormone, or alpha-MSH (in plain English: a natural hormone that helps control inflammation).
Is KPV legal to compound in 2026?
Not yet, at least not through a standard 503A pharmacy. Removal from Category 2 lifts a prohibition — it does not add KPV to the approved bulk substances list. That step needs a recommendation from the Pharmacy Compounding Advisory Committee, or PCAC (in plain English: the FDA's expert panel that decides what pharmacies may compound). Clearing Category 2 opened one door; KPV hasn't opened the second one yet.
When does the FDA review KPV?
The PCAC meets July 23-24, 2026. KPV-related bulk substances sit on the July 23 agenda alongside BPC-157, TB-500, and MOTS-c. Semax, Epitalon, and Emideltide (DSIP) follow on July 24. Seven peptides total are under review across both days for possible addition to the Section 503A Bulks List. As of this writing, the meeting has not happened. No vote, recommendation, or outcome exists yet.
What is KPV used for?
Researchers have nominated KPV for wound healing and inflammatory conditions, the use now under PCAC review. KPV entered mouse colon cells through the PepT1 transporter (in plain English: a doorway on gut cells that pulls in small fragments, like a mail slot for letters). It reduced colitis severity there (Dalmasso et al., Gastroenterology, 2008). Earlier work isolated the anti-inflammatory activity of this alpha-MSH fragment (Getting et al., 2003). This is mouse data, not a confirmed human benefit.
The Halftime POV
We'd rather explain the two-checkpoint distinction than let a "removed from Category 2" headline imply KPV is cleared. It isn't. We'll update this page when the PCAC votes.
Related reading:
- KPV: who asks about it
- PCAC July 2026 meeting: what's on the agenda
- 12 peptides removed from FDA restriction in 2026
- Category 2 and patient risk, explained
FAQ
Q: What is KPV Category 2 status? A: KPV was on the FDA's Category 2 list, which flagged it as a bulk substance that compounding pharmacies could not legally prepare under Section 503A. The FDA removed KPV from that list on April 15, 2026, lifting the prohibition flag but not granting compounding approval.
Q: Is KPV legal to compound in 2026? A: Not through a standard 503A pharmacy yet. Removal from Category 2 only lifts the safety-risk flag. KPV still needs a separate recommendation from the Pharmacy Compounding Advisory Committee before it can be added to the approved bulk substances list, and that review has not concluded.
Q: When does the FDA review KPV? A: The Pharmacy Compounding Advisory Committee discusses KPV-related bulk drug substances on July 23, 2026, alongside BPC-157, TB-500, and MOTS-c. As of this writing, that meeting has not occurred, and no vote or outcome has been announced.
Q: What is KPV used for? A: KPV's nominated use before the Pharmacy Compounding Advisory Committee is wound healing and inflammatory conditions. Mouse studies found it reduced colitis severity after entering colon cells through the PepT1 transporter, but this is animal data, not a confirmed human benefit (Dalmasso et al., Gastroenterology, 2008).
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We'll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we'll email you when we're live.
Sources
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee — FDA
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act — FDA (2026)
- Dalmasso G et al., KPV reduces colitis severity via the PepT1 transporter, Gastroenterology (2008)
- Getting SJ et al., anti-inflammatory activity of the alpha-MSH C-terminal fragment KPV (2003)
Frequently asked questions
What is KPV Category 2 status?
KPV was on the FDA's Category 2 list, which flagged it as a bulk substance that compounding pharmacies could not legally prepare under Section 503A. The FDA removed KPV from that list on April 15, 2026, lifting the prohibition flag but not granting compounding approval.
Is KPV legal to compound in 2026?
Not through a standard 503A pharmacy yet. Removal from Category 2 only lifts the safety-risk flag. KPV still needs a separate recommendation from the Pharmacy Compounding Advisory Committee before it can be added to the approved bulk substances list, and that review has not concluded.
When does the FDA review KPV?
The Pharmacy Compounding Advisory Committee discusses KPV-related bulk drug substances on July 23, 2026, alongside BPC-157, TB-500, and MOTS-c. As of this writing, that meeting has not occurred, and no vote or outcome has been announced.
What is KPV used for?
KPV's nominated use before the Pharmacy Compounding Advisory Committee is wound healing and inflammatory conditions. Mouse studies found it reduced colitis severity after entering colon cells through the PepT1 transporter, but this is animal data, not a confirmed human benefit (Dalmasso et al., Gastroenterology, 2008).
Keep reading
A licensed physician can build a protocol from your own labs.
Membership from $69/mo, including your onboarding panel. Each protocol is its own monthly subscription.